2024
945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Machiels J, Burtness B, Harrington K, Saba N, Tahara M, Crossman T, Hua L, Perera A, Theti D, Zografos E, Siu L. 945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2024, 35: s655. DOI: 10.1016/j.annonc.2024.08.2145.Peer-Reviewed Original Research
2023
PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412
Tahara M, Machiels J, Tao Y, Burtness B, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Swaby R, Zhang Y, Bidadi B, Siu L. PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412. Annals Of Oncology 2023, 34: s1380. DOI: 10.1016/j.annonc.2023.09.109.Peer-Reviewed Original Research
2022
LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)
Machiels J, Tao Y, Burtness B, Tahara M, Rischin D, Alves G, Lima I, Hughes B, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnal M, Licitra L, Swaby R, Zhang Y, Gumuscu B, Bidadi B, Siu L. LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2022, 33: s1399. DOI: 10.1016/j.annonc.2022.08.029.Peer-Reviewed Original Research
2021
P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009
Harrington K, Cohen E, Siu L, Rischin D, Licitra L, Vermorken J, Le Q, Tahara M, Machiels J, Hawk N, Ge J, Bidadi B, Swaby R, Burtness B. P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009. Oral Oncology 2021, 118: 10-11. DOI: 10.1016/s1368-8375(21)00381-x.Peer-Reviewed Original Research
2020
Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Greil R, Rischin D, Harrington K, Soulières D, Tahara M, de Castro G, Psyrri A, Baste N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Lin J, Swaby R, Gumuscu B, Burtness B. Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2020, 31: s660-s661. DOI: 10.1016/j.annonc.2020.08.1030.Peer-Reviewed Original ResearchChapter 11 Trials and tribulations: Clinical trials and the future
Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.Peer-Reviewed Original ResearchClinical trialsNeck cancerRecent landmark trialsRole of immunotherapyRisk stratification toolPromising clinical trialsMetastatic headPoor accrualSystemic treatmentLandmark trialsNeck specialistsStratification toolDedicated headTrialsCurrent standardCancerExciting advancesLack of fundingHeadImmunotherapyHPVHNSCCTherapyDiseasePathobiology
2019
Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgression
2018
Overview: The Pathobiology of Head and Neck Cancer
Burtness B, Golemis E. Overview: The Pathobiology of Head and Neck Cancer. Current Cancer Research 2018, 1-5. DOI: 10.1007/978-3-319-78762-6_1.Peer-Reviewed Original ResearchNeck cancerHPV-negative diseaseImmune checkpoint blockadeSquamous cell cancerHigh recurrence ratePathobiology of headEarly-stage cancerTumor suppressor gene mutationsSuppressor gene mutationsMultimodality therapyCheckpoint blockadeCytotoxic chemotherapyMetastatic diseaseAdvanced cancerCell cancerRecurrence rateHuman papillomavirusDevastating cancerStage cancerSubglottic larynxCancerPersonalized therapyGene mutationsPatientsTherapyTargeting the ErbB Family in Head and Neck Cancer
Kiseleva A, Beck T, Serebriiskii I, Liu H, Burtness B, Golemis E. Targeting the ErbB Family in Head and Neck Cancer. Current Cancer Research 2018, 7-61. DOI: 10.1007/978-3-319-78762-6_2.Peer-Reviewed Original ResearchPI3K/Akt/mTORSquamous cell carcinomaErbB receptor tyrosine kinase familyNovel therapeutic approachesAkt/mTORErbB family receptorsJAK1/STAT3PLC/PKCErbB family membersEGFR therapyCell carcinomaCommon therapyNeck cancerReceptor tyrosine kinase familyTherapeutic approachesNew therapiesCancer growthAbnormal expressionFamily receptorsTherapyTyrosine kinase familySCCHNErbB familyNormal cellsFamily membersAdjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database
Cheraghlou S, Kuo P, Mehra S, Agogo GO, Bhatia A, Husain ZA, Yarbrough WG, Burtness BA, Judson BL. Adjuvant therapy in major salivary gland cancers: Analysis of 8580 patients in the National Cancer Database. Head & Neck 2018, 40: 1343-1355. PMID: 29756412, DOI: 10.1002/hed.24984.Peer-Reviewed Original ResearchConceptsNational Cancer Data BaseLate-stage diseaseAdjuvant treatmentSalivary gland cancerAdverse featuresAdjuvant radiotherapyImproved survivalGland cancerMajor salivary gland cancerAddition of chemotherapyNational Cancer DatabaseAdjuvant therapySurvival benefitRetrospective studyCancer DatabaseImproved outcomesCancer casesPatientsChemotherapyDiseaseTreatmentRadiotherapySurvivalCancerTherapy
2017
Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.Peer-Reviewed Original ResearchConceptsClinical trialsHNSCC cellsMatrix metalloproteinasesHuman papillomavirus-associated headNeck squamous cell carcinomaSquamous cell carcinomaAbility of HPVClin Cancer ResTumor cell proliferationNeck cancer cellsWindow trialsCell carcinomaEffective therapyPreclinical modelsHPVHPV oncogenesMouse modelMouse blood vesselsDNA demethylating agentHNSCCXenografted tumorsHPV genesIFN responseTherapyTumor samplesSurvival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy
Kelly J, An Y, Park H, Yarbrough W, Burtness B, Husain Z. Survival Outcomes Among Human Papillomavirus-Associated Oropharyngeal Squamous Cell Cancer Patients Treated with Upfront Surgery Versus Definitive Chemoradiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: s43-s44. DOI: 10.1016/j.ijrobp.2017.06.114.Peer-Reviewed Original Research
2015
Head and Neck Cancers, Version 1.2015.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. Journal Of The National Comprehensive Cancer Network 2015, 13: 847-55; quiz 856. PMID: 26150579, PMCID: PMC4976490, DOI: 10.6004/jnccn.2015.0102.Peer-Reviewed Original Research
2014
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.
Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. Journal Of The National Comprehensive Cancer Network 2014, 12: 1454-87. PMID: 25313184, DOI: 10.6004/jnccn.2014.0142.Peer-Reviewed Original ResearchConceptsGlottic laryngeal cancerClinical practice guidelinesLaryngeal cancerNeck cancerPractice guidelinesNCCN Clinical Practice GuidelinesEarly-stage primaryExcellent cure ratesPrinciples of surgeryDental evaluationCure rateRegional nodesRadiation therapyLymphatic drainageEarly symptomsCancerCommon typeOncologyGuidelinesEarly stagesHoarsenessSurgeryTherapySymptomsHeadTargeted agents: management of dermatologic toxicities.
Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsDermatologic side effectsQuality of lifeDermatologic toxicitiesCutaneous complicationsSkin complicationsTherapeutic mainstayReceptor inhibitorsCommon culpritsToxicity profileMTOR inhibitorsSide effectsCosmetic issuesAnticancer treatmentPotential infectionComplicationsTreatmentInhibitorsTherapyAgentsCancerInfectionMainstayBRAFNew directions in perioperative management of locally advanced esophagogastric cancer.
Burtness B, Ilson D, Iqbal S. New directions in perioperative management of locally advanced esophagogastric cancer. American Society Of Clinical Oncology Educational Book 2014, e172-8. PMID: 24857100, DOI: 10.14694/edbook_am.2014.34.e172.Peer-Reviewed Original ResearchProjections: Novel Therapies for HPV-Negative Cancers of the Head and Neck
Burtness B. Projections: Novel Therapies for HPV-Negative Cancers of the Head and Neck. Current Cancer Research 2014, 343-359. DOI: 10.1007/978-1-4614-8815-6_17.Peer-Reviewed Original ResearchHuman papillomavirusNeck cancerNovel therapiesHPV-negative cancersPD-1 inhibitorsIntensification of therapyHPV-negative headReceptor c-MetAdvanced headImmune suppressionCTLA-4Larynx cancerC-MetCurrent trialCancerTherapyMolecular targetsErbB/Radiation techniquesFamily membersBiomolecular profileHeadPatientsPapillomavirusNeck
2013
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug DesignDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyPapillomaviridaeProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsHPV-negative headNeck cancerHuman papillomavirusEGFR inhibitionSingle-agent cetuximabLow cure rateMonoclonal antibody cetuximabActive therapyCytotoxic chemotherapyDisease survivalCure rateMechanisms of resistanceAntibody cetuximabResponse rateCetuximabEGFRNovel targetReceptor tyrosine kinasesCancerTherapyHistone deacetylaseChemotherapyHabitual exposureModest effectNuclear functions
2012
Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”
Burtness B, Marur S, Bauman JE, Golemis EA, Mehra R, Cohen SJ. Comment on “Epidermal Growth Factor Receptor Is Essential for Toll-Like Receptor 3 Signaling”. Science Signaling 2012, 5: lc5. PMID: 23233526, DOI: 10.1126/scisignal.2003734.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptorGrowth factor receptorToll-like receptor 3Functional innate immune responseFactor receptorInnate immune responseFulminant infectionCombination therapyImmune responseTumor growthReceptor 3Mammalian targetCancer therapeuticsReceptorsMTORPatientsBody of literatureTherapyTumorsInfectionDysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue
Sopka D, Li T, Lango M, Mehra R, Burtness B, Flieder D, Ridge J, Galloway T. Dysplasia at the Margin? Investigating the Case for Subsequent Therapy in Squamous Cell Carcinoma of the Oral Tongue. International Journal Of Radiation Oncology • Biology • Physics 2012, 84: s205. DOI: 10.1016/j.ijrobp.2012.07.531.Peer-Reviewed Original Research